Valneva: applications for expanded indications for Ixchiq

(CercleFinance.com) - Valneva announces that it has submitted applications to expand the indication for Ixchiq to potentially extend the use of its chikungunya vaccine to adolescents aged 12 to 17 in Europe and Canada.


The Health Canada submission also includes data on antibody persistence for up to two years, a key differentiator of the Ixchiq vaccine that was already included in the initial submission to the European Medicines Agency (EMA).

Valneva also plans to submit data this year to extend the use of the vaccine in the United States. Launch in that country is underway, while first sales in Canada and Europe are scheduled for the fourth quarter of 2024.

Copyright (c) 2024 CercleFinance.com. All rights reserved.